Literature DB >> 2273643

Hemodynamic changes following long-term administration of CS-905, a novel dihydropyridine calcium blocker, in conscious SHR.

K Oizumi1, H Nishino, S Miyake, H Shiga, T Sada, M Miyamoto, H Koike.   

Abstract

To investigate the central and regional hemodynamics after long-term administration of CS-905, a novel calcium blocker, we administered the agent (1 and 3 mg/kg/day) for 15 weeks in spontaneously hypertensive rats. At the end of the dosing period, hemodynamic changes were examined using the radioactive microsphere technique. CS-905 produced a sustained dose-dependent antihypertensive effect without inducing tolerance during the 15-week dosing period and prevented cardiac hypertrophy. The agent increased cardiac output, decreased blood pressure and thus decreased total peripheral resistance in a dose-related manner. Regional blood flows measured by the microsphere technique were increased in the kidney and brain despite the lowered blood pressure. There was no organ where regional blood flow was decreased. These changes after chronic treatment with CS-905 would be beneficial in the long-term therapy of hypertension.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2273643     DOI: 10.1254/jjp.54.1

Source DB:  PubMed          Journal:  Jpn J Pharmacol        ISSN: 0021-5198


  4 in total

Review 1.  Therapeutic Usefulness of a Novel Calcium Channel Blocker Azelnidipine in the Treatment of Hypertension: A Narrative Review.

Authors:  C Venkata S Ram
Journal:  Cardiol Ther       Date:  2022-08-13

Review 2.  Azelnidipine.

Authors:  Keri Wellington; Lesley J Scott
Journal:  Drugs       Date:  2003       Impact factor: 9.546

3.  New Generation Calcium Channel Blockers in Hypertensive Treatment.

Authors:  Yuri Ozawa; Koichi Hayashi; Hiroyuki Kobori
Journal:  Curr Hypertens Rev       Date:  2006-05-01

4.  Azelnidipine inhibits cultured rat aortic smooth muscle cell death induced by cyclic mechanical stretch.

Authors:  Jing Zhao; Kentaro Ozawa; Yoji Kyotani; Kosuke Nagayama; Satoyasu Ito; Akira T Komatsubara; Yuichi Tsuji; Masanori Yoshizumi
Journal:  PLoS One       Date:  2014-07-17       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.